

December 10, 2021

To whom it may concern:

Company Name	TOHO HOLDINGS CO., LTD.
Corporate Representative	Atsushi Udoh, President and Representative Director (First Section of Tokyo Stock Exchange Securities Code:8129)
Contact:	Makoto Kawamura, Director and General Manager, Corporate Management Division and Corporate Planning and Investor Relations Department (TEL: 81-3-6838-2803)

Notice Regarding Agreement for Business Alliance with CellGenTech, Inc.

TOHO HOLDINGS CO., LTD. (Headquarters: Tokyo; President and Representative Director: Atsushi Udoh; hereinafter “TOHO HOLDINGS”) announces that it has invested in CellGenTech, Inc. (Headquarters: Chiba; President & CEO: Masayuki Aso; hereinafter “CellGenTech”), as described below.

1. Purpose of business alliance

TOHO HOLDINGS is a corporate group active in medical, nursing and healthcare fields, engaged in pharmaceutical wholesaling, dispensing pharmacy, manufacturing and sales of pharmaceuticals, and development and provision of customer support systems under the corporate slogan “Total Commitment to Good Health”. TOHO HOLDINGS also proactively promotes initiatives for regional medical collaboration, nursing and home care.

In collaboration with Chiba University, CellGenTech is developing cell-based medicines for gene therapy using adipocytes, aiming to commercialize regenerative medicine and gene therapy medicines that can provide long-term therapeutic effects with a single transplant by taking advantage of the stable life span of adipocytes. Some medicines using this technology are already in the clinical trial stage and are close to commercialization.

TOHO HOLDINGS highly appreciates the business activities of CellGenTech and through this investment intends to support the research and development promoted by CellGenTech and to strengthen its efforts in specialty pharmaceuticals, including medicines for gene therapy and regenerative medical products.

2. Overview of CellGenTech

- (1) Company name: CellGenTech, Inc.
- (2) Location: Chiba-dai Inohana Innovation Plaza
1-8-15, Inohana, Chuo-ku, Chiba-city, Chiba
- (3) Representative: Masayuki Aso, President & CEO
- (4) Established: October 20, 2003
- (5) Business content: Research and development of human adipocyte-based medicines for gene therapy
- (6) Capital: 363.49 million yen
- (7) Fiscal year end: December 31
- (8) Number of employees: 25

3. Forward looking outlook

The impact of this business alliance on the Company’s business performance is expected to be minimal, but the Company will disclose any impact promptly if it becomes necessary to do so in the future.